Contineum Therapeutics (CTNM) Insider Ware Buys 19,000 Shares

Olivia Ware, an insider at Contineum Therapeutics, Inc. (NasdaqGS: CTNM), purchased 19,000 shares of the company on June 26, 2026. This transaction was not part of a pre-arranged plan, indicating a direct buy by Ware.

Insider Buying and Selling at Contineum Therapeutics, Inc.

On the same day, other insiders including Lori Lyons-Williams, Gines Diego Miralles, Todd Brady, Sarah Boyce, and Evert Schimmelpennink each bought 19,000 shares of Contineum Therapeutics. These transactions, like Ware's, were not conducted under Rule 10b5-1 plans.

Other Institutional Activity in Contineum Therapeutics

Among institutional investors, Janus Henderson Group PLC increased its holdings by 285,857 shares, reaching a total of 2,734,836 shares valued at about $35.6 million, marking an 11.7% increase. Millennium Management LLC also boosted its stake significantly, adding 704,762 shares to hold 1,535,449 shares worth approximately $20.1 million, an 84.8% rise. Conversely, Franklin Resources Inc trimmed its position by 40,140 shares, holding 1,839,227 shares valued at $24.0 million, a 2.1% decrease. Balyasny Asset Management L.P. reduced its holdings by 157,165 shares, ending with 1,685,635 shares worth about $22.0 million, an 8.5% decrease.

Contineum Therapeutics, Inc. Stock Up 4.9%

Shares of Contineum Therapeutics traded near $13.36 on Saturday. The company, with a market capitalization of approximately $530.5 million, operates in the biotechnology sector. It has a forward P/E ratio of -7.8 and a beta of 0.89. The stock's 52-week range is between $3.72 and $16.33, with a 50-day moving average of $13.02 and a 200-day moving average of $12.53. The company maintains a strong liquidity position with a current ratio of 38.0 and a quick ratio of 37.0, while its debt-to-equity ratio stands at 2.78.

Analysts Set New Price Targets

On May 14, 2026, Morgan Stanley maintained its 'hold' rating on Contineum Therapeutics with a price target of $16. Previously, in March, Baird reiterated a 'buy' rating with a target of $20. RBC Capital also maintained a 'buy' stance with a target price of $22. The consensus among six analysts is a 'strong buy', with a mean target price of $22.33.

About Contineum Therapeutics

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. It focuses on developing small molecule therapies for neuroscience, inflammation, and immunology. The company's leading product candidate, PIPE-791, is designed for treating idiopathic pulmonary fibrosis and chronic pain. Another asset, PIPE-307, targets depression and relapse-remitting multiple sclerosis. Led by CEO Carmine N. Stengone, the company employs 51 people.

Bottom Line

Olivia Ware's recent purchase of Contineum Therapeutics shares signals confidence in the company's potential. Investors often track insider buys for insights into a company's prospects. While insider transactions provide valuable information, they are backward-looking and part of routine disclosures.